Galmed Pharmaceuticals: A Profitable Quarter

Galmed Pharmaceuticals just dropped a profitable Q2, reporting a net income of $2.5 million—that's 63 cents a share! The biotech firm specializing in liver disease therapies is turning heads, potentially boosting investor confidence and paving the way for future research and development. Is this the start of a profitable trend for Galmed, or just a one-time event? All eyes are on their next move. Hosted on Acast. See acast.com/privacy for more information.